Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants With Severe Alopecia Areata

Inclusion Criteria:

• Have severe alopecia areata (AA) that meets all of the following criteria:
  • Hair loss encompassing ≥50% and ≤90% of the scalp, as measured by Severity of Alopecia Tool (SALT) score
  • The duration of the current episode of severe AA is at least 6 months and does not exceed 4 years
  • No significant spontaneous hair regrowth in the investigator’s opinion for at least 6 months
  • Agree not to use any AA treatments during the study
  • Ages 18 to 50 years

Exclusion Criteria:

• Primarily “diffuse” type of AA (characterized by diffuse hair shedding)
• Are currently experiencing other forms of alopecia
• Participants who, in the opinion of the investigator, are currently experiencing or have a history of unstable concomitant disease that requires frequent hospitalizations, and/or frequent use of systemic immunosuppressants that may interfere with participation in the study
• Have received oral JAK Inhibitors in the past
• Have had any major surgery within 8 weeks prior to screening or will require major surgery during the study
• Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness